Since the outbreak of the epidemic caused by SARS-CoV-2, Clongene has taken swift actions and has successfully developed three kinds of COVID-19 detection reagents including antigen rapid test, antibody rapid test and nucleic acid test, which have continued to provide support for more than 100 countries around the world to fight the epidemic.
Clungene COVID-19 detection reagents have obtained the CE certification in EU, the TGA certification in Australia and some certifications from different countries, which demonstrate the quality of our products are approved by related government institutions.
For qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab, nasal swab .
For the qualitative detection of SARS-CoV-2, influenza A virus, influenza B virus, respiratory syncytial virus (RSV) and adenovirus antigens in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory infection.
For the qualitative detection of SARS-CoV-2, influenza A virus, influenza B virus, human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), adenovirus (AdV), Mycoplasma pneumoniae (MP) antigens in nasopharyngeal swab or oropharyngeal swab specimens from individuals with signs and symptoms of respiratory infection.
For the qualitative detection of SARS-CoV-2, respiratory syncytial virus (RSV), influenza A and influenza B viral antigens in nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory infection.
For qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab, nasal swab or oropharyngeal swab.
For qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab, nasal swab or oropharyngeal swab.
Infectious Disease
Drugs of Abuse
Hormones
Tumor Markers
Cardiac Markers
Thrombus
Inflammation
Serum Proteins
Reproductive Health
Food Safety
Animal Disease
PCR Reagent
Others
